Search Results - "Gries, Katharine S"

The Effect of Endometriosis Symptoms on Absenteeism and Presenteeism in the Workplace and at Home by Soliman, Ahmed M, Coyne, Karin S, Gries, Katharine S, Castelli-Haley, Jane, Snabes, Michael C, Surrey, Eric S

“…Characterized by pain symptoms, endometriosis affects women's productivity in their prime working years. To evaluate the effect of individual endometriosis…”
Get full text

Response scale selection in adult pain measures: results from a literature review by Safikhani, Shima, Gries, Katharine S., Trudeau, Jeremiah J., Reasner, David, Rüdell, Katja, Coons, Stephen Joel, Bush, Elizabeth Nicole, Hanlon, Jennifer, Abraham, Lucy, Vernon, Margaret

“…Background The purpose of this literature review was to examine the existing patient-reported outcome measurement literature to understand the empirical…”
Get full text

Using a digital patient powered research network to identify outcomes of importance to patients with multiple myeloma by Gries, Katharine S., Fastenau, John

“…Background Social media platforms give patients a voice by allowing them to discuss their health and connect with others. These unfiltered and genuine reports…”
Get full text

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial by Knop, Stefan, Mateos, Maria-Victoria, Dimopoulos, Meletios A, Suzuki, Kenshi, Jakubowiak, Andrzej, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Usenko, Ganna, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Losava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Wang, Jianping, Wroblewski, Susan, Kudva, Anupa, Gries, Katharine S, Fastenau, John, San-Miguel, Jesus, Cavo, Michele

“…Abstract Background In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and…”
Get full text

Symptom burden and health-related quality of life impacts of smoldering multiple myeloma: the patient perspective by Jean-Baptiste, Milenka, Gries, Katharine S., Lenderking, William R., Fastenau, John

“…Background Smoldering multiple myeloma (SMM) is an early form of multiple myeloma (MM). SMM is typically considered asymptomatic, and research on how it…”
Get full text

The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies by Crawford, Rebecca, Gries, Katharine S., Valluri, Satish, Fastenau, John, Morrison, Ross, Yeh, Tzu‐Min, Olyslager, Yunsi, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Doward, Lynda

“…Background Relapsed refractory multiple myeloma (RRMM) is a disease that is nonresponsive or progressive on therapy, and although patients can achieve…”
Get full text

Preferences for Prostate Cancer Outcomes: A Comparison of the Patient Perspective, the General Population Perspective, and a Population at Risk for Prostate Cancer by Gries, Katharine S., PharmD, PhD, Regier, Dean A., PhD, Ramsey, Scott D., PhD, MD, Patrick, Donald L., PhD, MSPH

“…Abstract Objective To collect disease-specific and generic preference values for three populations. Methods Prostate cancer-specific health states were…”
Get full text

Literature review to characterize the empirical basis for response scale selection in pediatric populations by Naegeli, April N., Hanlon, Jennifer, Gries, Katharine S., Safikhani, Shima, Ryden, Anna, Patel, Mira, Crescioni, Mabel, Vernon, Margaret

“…Background Despite the importance of response option selection for patient-reported outcome measures, there seems to be little empirical evidence for the…”
Get full text

Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma by Tervonen, Tommi, Duenas, Ashley, Collacott, Hannah, Lam, Annette, Gries, Katharine S., Carson, Robin, Trevor, Nicola, Krucien, Nicolas, He, Jianming

“…To examine how disease status and current health state influence treatment preferences of patients with multiple myeloma (MM). Participants with MM from…”
Get full text

MCDA swing weighting and discrete choice experiments for elicitation of patient benefit‐risk preferences: a critical assessment by Tervonen, Tommi, Gelhorn, Heather, Sri Bhashyam, Sumitra, Poon, Jiat‐Ling, Gries, Katharine S., Rentz, Anne, Marsh, Kevin

“…Purpose Multiple criteria decision analysis swing weighting (SW) and discrete choice experiments (DCE) are appropriate methods for capturing patient…”
Get full text

Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss by Gelhorn, Heather L., Gries, Katharine S., Speck, Rebecca M., Duus, Elizabeth M., Bourne, Richard K., Aggarwal, Dimple, Cella, David

“…Purpose Comprehensive (qualitative and quantitative) assessments of the 12-item functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia…”
Get full text

Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma by Gries, Katharine S., Fastenau, John, Seo, Caroline, Potrata, Barbara, Iaconangelo, Charles, Serrano, Daniel

“…This study aimed to develop and assess the content validity of a patient-reported outcomes (PROs) instrument to measure symptoms and impacts experienced by…”
Get full text

Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial by Hungria, Vania, Beksac, Meral, Weisel, Katja C., Nooka, Ajay K., Masszi, Tamas, Spicka, Ivan, Munder, Markus, Mateos, María‐Victoria, Mark, Tomer M., Qi, Ming, Qin, Xiang, Fastenau, John, Spencer, Andrew, Sonneveld, Pieter, Garvin, Wendy, Renaud, Thomas, Gries, Katharine S.

“…Summary In the phase III CASTOR trial, daratumumab, bortezomib and dexamethasone (D‐Vd) significantly extended progression‐free survival compared with…”
Get full text

Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial by Plesner, Torben, Dimopoulos, Meletios A., Oriol, Albert, San‐Miguel, Jesus, Bahlis, Nizar J., Rabin, Neil, Suzuki, Kenshi, Yoon, Sung‐Soo, Ben‐Yehuda, Dina, Cook, Gordon, Goldschmidt, Hartmut, Grosicki, Sebastian, Qin, Xiang, Fastenau, John, Garvin, Wendy, Carson, Robin, Renaud, Thomas, Gries, Katharine S.

“…Summary In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D‐Rd) significantly improved progression‐free survival in…”
Get full text

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial by Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z, Kumar, Shaji, Bahlis, Nizar J, Hulin, Cyrille, Orlowski, Robert Z, Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, Van Rampelbergh, Rian, Uhlar, Clarissa M, Wang, Jianping, Kobos, Rachel, Gries, Katharine S, Fastenau, John, Weisel, Katja

“…To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs)…”
Get full text

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence by Campbell, Jonathan D, Gries, Katharine S, Watanabe, Jonathan H, Ravelo, Arliene, Dmochowski, Roger R, Sullivan, Sean D

“…Treatment options for overactive bladder (OAB) with urinary urge incontinence (UUI) refractory to oral antimuscarinics include: botulinum toxin type A (BoNTA),…”
Get full text

Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial by Terpos, Evangelos, Dimopoulos, Meletios A., Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Pompa, Alessandra, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria‐Victoria, Einsele, Hermann, Orfanidis, Ioannis, Gries, Katharine S., Fastenau, John, Liu, Kevin, He, Jianming, Kampfenkel, Tobias, Qiu, Yanping, Amin, Himal, Carson, Robin, Sonneveld, Pieter

“…In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D‐Pd) significantly reduced the rate of disease progression or…”
Get full text

Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany by He, Jianming, Duenas, Ashley, Collacott, Hannah, Lam, Annette, Gries, Katharine S., Carson, Robin, Potthoff, Dietrich, Trevor, Nicola, Tervonen, Tommi

“…Background The current standard of care for multiple myeloma requires several regimens of treatment, with patients experiencing high symptom burden and side…”
Get full text

Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN by Silbermann, Rebecca, Laubach, Jacob, Kaufman, Jonathan L., Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Bumma, Naresh, Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Gries, Katharine S., Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Voorhees, Peter M., Usmani, Saad Z., Richardson, Paul G.

“…In the phase 2 GRIFFIN trial (ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D‐RVd) improved…”
Get full text

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma by Mateos, Maria-Victoria, Rigaudeau, Sophie, Basu, Supratik, Spicka, Ivan, Schots, Rik, Wrobel, Tomasz, Cook, Gordon, Beksac, Meral, Gries, Katharine S, Kudva, Anupa, Tromp, Brenda, Van Rampelbergh, Rian, Pei, Huiling, Wroblewski, Susan, Carson, Robin, Delioukina, Maria, White, Darrell

“…Introduction Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or…”
Get full text